A Phase 1 Dose Escalation Study of IPI-493
Public ClinicalTrials.gov record NCT00724425. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of IPI-493 Orally Administered to Patients With Advanced Malignancies
Study identification
- NCT ID
- NCT00724425
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Enrollment
- 53 participants
Conditions and interventions
Conditions
Interventions
- IPI-493 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2008
- Primary completion
- Jun 30, 2011
- Completion
- Jun 30, 2011
- Last update posted
- Apr 14, 2015
2008 – 2011
United States locations
- U.S. sites
- 5
- U.S. states
- 4
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Premiere Oncology, Arizona | Scottsdale | Arizona | 85260 | — |
| San Diego Pacific Oncology and Hematology Associates | Encinitas | California | 92024 | — |
| Premiere Oncology, California | Santa Monica | California | 90404 | — |
| Univeristy of Colorado Health Science Center | Aurora | Colorado | 80045 | — |
| Mary Crowley Cancer Research Center | Dallas | Texas | 75201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00724425, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2015 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00724425 live on ClinicalTrials.gov.